EGCG downregulates M1 markers (IL-6, TNF-, and IL-1) and upregulates M2 markers (IL-10 and NQO1) in microglia, thereby modulating the M1/M2 ratio and mitigating neurotoxicity and neuronal damage arising from microglial hyperactivity (13)
Formulation differences The dose flexibility of compounded formulations is actually an advantage for some patients
Not FDA-approved and associated with significant safety concerns including dangerous nausea, uncontrolled melanocytic changes (nevi/moles), hypertension, and priapism
The program includes a comprehensive metabolic assessment, ongoing medical monitoring, and long-term follow-up - not a one-time prescription
Management : wide local excision (margins: 0.52 cm by stage)
Kidney Int 44:107114 Brink M, Wellen J, Delafontaine P (1996) Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism